MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-19-0175893
Wardex Pharmaceuticals Private Limited - pharma in Chennai, Tamil Nadu, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹158.1 Cr
▲ 8% YoY
Net profit · FY 2025
₹21.88 Cr
Net margin 13.8%
EBITDA · FY 2025
₹30.92 Cr
EBITDA margin 19.6%
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹41.98 Lakh
Issued & subscribed
Open charges
₹30 Lakh
Satisfied ₹1.64 Cr
Company age
80 yrs
Est. 1946
Employees · EPFO
102
Provident fund records
About Wardex Pharmaceuticals Private Limited
Data last updated:
Wardex Pharmaceuticals Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 December 1946 and has been in existence for over 80 years.
Its director Postel Pascal and family are #893 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U51397TN1946PTC005759. Its GSTIN is 33AAACW1036D1ZZ (Tamil Nadu). The company holds 18 GST registrations, of which 14 are active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹41.98 Lakh. It was formerly known as Ward Blenkinsop & Co. (India) Private Limited and Ward Blenkinsop & Co. (India) Limited. It is led by directors including Alexandre Johan Pascal Postel (Managing Director) and Jagdish Purushottamdas Mehta.
Its last annual general meeting (AGM) was held on 27 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 55 Nelson Manicka Mudaliarroad Aminjikarai Madras – 29, Chennai, Tamil Nadu, India – 600029.
As per the financials filed for FY 2025, the company reported a revenue of ₹158.1 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹21.88 Cr (net margin 13.8%) and EBITDA of ₹30.92 Cr (EBITDA margin 19.6%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 8% over five years.
The company has about 102 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹30 Lakh and satisfied charges of ₹1.64 Cr on record. Court records list 28 cases involving the company, including 26 filed by the company and 2 filed against it; 7 cases are pending. The company has 5 deals on record (5 secondary share transfers); the latest was in March 2024. Its 5 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 2 smaller; the largest is Elysium Pharmaceuticals Ltd with revenue of ₹159.55 Cr. The company has 3 MSME Form 1 returns on record between 2019 and 2020, listing 38 overdue payments to 25 micro and small suppliers.
Wardex Pharmaceuticals Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0175893). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website francoindian.com.
Company details
CIN U51397TN1946PTC005759
Registration Number 005759
Incorporation Date 18 December 1946
ROC Chennai
Listing Status Unlisted
Company Status Active
Date of Last AGM 27 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0175893
Name history
Wardex Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Ward Blenkinsop & Co. (India) Private Limited, and Ward Blenkinsop & Co. (India) Limited. The current legal name is Wardex Pharmaceuticals Private Limited.
| Company Name | Status |
|---|---|
| Wardex Pharmaceuticals Private Limited | Current |
| Ward Blenkinsop & Co. (India) Private Limited | Previous |
| Ward Blenkinsop & Co. (India) Limited | Previous |
Key People
Alexandre Johan Pascal Postel Managing Director Errol James Desouza Additional Director Jagdish Purushottamdas Mehta Director Recognitions & Rankings of Wardex Pharmaceuticals
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #893 Postel Pascal & family ₹3,300 Cr
Contact details
Wardex Pharmaceuticals Private Limited's registered office is in Chennai, Tamil Nadu. Its website is francoindian.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address55 Nelson Manicka Mudaliarroad Aminjikarai Madras – 29, Chennai, Tamil Nadu, India – 600029
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Wardex Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Wardex Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Wardex Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Wardex Pharmaceuticals Private Limited, buy the company report.
Financials of Wardex Pharmaceuticals Private Limited
FY 2024 filings availableWardex Pharmaceuticals Private Limited reported revenue of ₹158.1 Cr (up 8% YoY) for FY 2025.
Revenue · FY 2025
₹158.1 Cr ▲ 8%
Net profit · FY 2025
₹21.88 Cr margin 13.8%
EBITDA · FY 2025
₹30.92 Cr margin 19.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 8%
3 years · compounded
▲ 2%
5 years · compounded
▲ 8%
EBITDA CAGR growth
1 year
▲ 8%
3 years · compounded
▲ 7%
5 years · compounded
▲ 6%
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 8% growth in the latest year. EBITDA rose 8% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹30.92 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹21.88 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 19.6% | ||||
| Net Profit Margin | 13.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Wardex Pharmaceuticals Private Limited, buy the company report.
Board of directors of Wardex Pharmaceuticals Private Limited
Wardex Pharmaceuticals has 7 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Errol James Desouza Also directs: Princeps Pharmaceuticals Private Limited, Franco Indian Medicare Pvt Ltd, Franco Indian Therapeutics Pvt. Ltd. and 5 more | Additional Director | 28 Jan 2025 | 1 Years 9 Months | Current |
| Jagdish Purushottamdas Mehta | Director | 19 Mar 2014 | 12 Years 7 Months | Current |
| Syed Asif Raza Rizvi | Director | 26 Feb 2021 | 5 Years 8 Months | Current |
| Vitalapuram Rajangam Krishna Subramanian Also directs: Princeps Pharmaceuticals Private Limited | Director | 01 Feb 1999 | 27 Years 8 Months | Current |
| Venkatraman Subramaniam | Director | 27 Jan 2018 | 8 Years 9 Months | Current |
| Pascal Postel Also directs: Princeps Pharmaceuticals Private Limited, Franco Indian Medicare Pvt Ltd, Franco Indian Therapeutics Pvt. Ltd. and 4 more | Director | 31 Dec 2020 | 5 Years 9 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Wardex Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Elysium Pharmaceuticals Ltd | ₹159.55 Cr (FY 2024) | -26.0% | Vadodara, Gujarat, India | |||
| VHB Medi Sciences Limited | ₹159.28 Cr (FY 2025) | 14.0% | Kandivlai West, Maharashtra, India | |||
| Jenburkt Pharmaceuticals Ltd | ₹158.41 Cr (FY 2025) | 8.0% | Mumbai, Maharashtra, India | |||
| Wardex Pharmaceuticals Private Limitedthis company | ₹158.1 Cr (FY 2025) | ₹21.88 Cr | 13.8% | 8.0% | 102 | Chennai, Tamil Nadu, India |
| Nitin Lifesciences Limited | ₹157.19 Cr (FY 2025) | 7.0% | Paonta Sahib, Himachal Pradesh, India | |||
| Wings Pharmaceuticals Pvt Ltd | ₹155.72 Cr (FY 2025) | 12.0% | New Delhi, Delhi, India |
To see the full peer comparison of Wardex Pharmaceuticals Private Limited, buy the company report.
Auditor
Wardex Pharmaceuticals Private Limited is audited by R . JANAKIRAMAN & CO. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| R . JANAKIRAMAN & CO. | FY 2024 | 001263S |
Shareholding
The shareholding of Wardex Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Wardex Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹30 Lakh
Satisfied charges
₹1.64 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 21 Dec 1982 | 90299368 | Catholic Syrian Bank Ltd. | ₹30 Lakh | Open | |
| 26 Sep 2014 | 10524177 | Bnp Paribas | ₹75 Lakh | Satisfied | |
| 20 Sep 1996 | 90300649 | Banque Nationale De Paris | ₹69 Lakh | Satisfied | |
| 10 Nov 1978 | 90299117 | Banque Natinale De Paris | ₹20 Lakh | Satisfied |
To see the full charge records of Wardex Pharmaceuticals Private Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Wardex Pharmaceuticals Private Limited has 5 deals on record (5 secondary share transfers); the latest was in March 2024.
Total deals
5
Secondary share transfers
5
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Secondary share transfer | Undisclosed | Seller: 2 individuals |
| Feb 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Sep 2011 | Secondary share transfer | Undisclosed | Buyer: Franco-Indian Holdings Private Limited , an individual Seller: Curabest Investments Private Limited , Pharmabest Investments Private Limited , Medibest Investments Private Limited , an individual |
| Sep 2008 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Franco Indian Research Private Limited |
| Mar 2007 | Secondary share transfer | Undisclosed | Buyer: Ward Pharmaceuticals Limited Seller: Dolphin Pharmaceuticals SA |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Wardex Pharmaceuticals Private Limited has 28 court cases on record: 26 filed by Wardex Pharmaceuticals, 2 filed against it. 7 cases are pending and 21 are disposed.
Total cases
28
Filed by the company
26
Filed against the company
2
Pending
7
Disposed
21
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 26 | 1 | 7 |
| District courts | 1 | 1 | 0 |
| Supreme Court | 1 | 0 | 0 |
Cases on record (5 of 28)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, MAHARASHTRA | Court case (COMIP) | Filed by the company against Psychotropics India Limited | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed by the company against Psychotropics India Limited | Disposed |
| Bombay High Court | Court case (CHS) | Filed by the company against Medley Pharmaceuticals and Anr | Disposed |
| Bombay High Court | Court case (CHS) | Filed by the company against Alto Healthcare Pvt. Ltd. and Anr | Disposed |
| Bombay High Court | Court case (APP) | Filed by the company against Medley Pharmaceuticals and Anr | Disposed |
To see the full case history of Wardex Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Wardex Pharmaceuticals Private Limited has 3 MSME Form 1 returns on record between 2019 and 2020, listing 38 overdue payments to 25 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 25)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| M/S.Imperial Enterprisors | |||
| Quality Printing & Stationery Concern(1997)Private Limited | |||
| U D Caps Limited | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Wardex Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Wardex Pharmaceuticals has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
Wardex Pharmaceuticals Private Limited has a workforce of 102 employees on its EPFO records as of Aug 30, 2025, across 3 active EPFO establishments.
Employee count
102
Active EPFO establishments
3
Employee growth
-6.42%
GST
Wardex Pharmaceuticals has 18 GST registrations: 14 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
18
Active
14
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACW1036D1ZZ | Tamil Nadu | Active | 01 Jul 2017 |
| 07AAACW1036D1ZU | Delhi | Active | 01 Jul 2017 |
| 08AAACW1036D1ZS | Rajasthan | Active | 01 Jul 2017 |
| 09AAACW1036D1ZQ | Uttar Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Wardex Pharmaceuticals Private Limited, buy the company report.
Recent activity
Wardex Pharmaceuticals Private Limited has 21 board changes on record since 1999: 7 appointments and 14 cessations. The latest: Errol James Desouza was appointed as Additional Director on 28 Jan 2025.
Charges
A charge registered on 26 Sep 2014 via Charge ID 10524177 with Bnp Paribas was fully satisfied on 22 Apr 2025.
Charges
A charge registered on 20 Sep 1996 via Charge ID 90300649 with Banque Nationale De Paris was fully satisfied on 22 Apr 2025.
Charges
A charge registered on 10 Nov 1978 via Charge ID 90299117 with Banque Natinale De Paris was fully satisfied on 22 Apr 2025.
Appointed
Errol James Desouza was appointed as Additional Director.
AGM
Wardex Pharmaceuticals Private Limited last Annual general meeting of members was held on 27 Sep 2024 as per latest MCA records.
Filing
Wardex Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chennai.
Ceased
Subhagmal Mohanchand Dadha ceased to be Director.
Ceased
Pascal Postel ceased to be Additional Director.
Ceased
Shahida Pascal Postel ceased to be Additional Director.
Ceased
Syed Asif Raza Rizvi ceased to be Additional Director.
Appointed
Syed Asif Raza Rizvi was appointed as Director.
Ceased
Noel Christopher Amanna ceased to be Director.
23 earlier events are in the company report.
Frequently asked questions
Wardex Pharmaceuticals is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 December 1946 (80+ years old) and is registered under CIN U51397TN1946PTC005759.
Wardex Pharmaceuticals has 7 current directors:
- Alexandre Johan Pascal Postel - Managing Director
- Errol James Desouza - Additional Director
- Jagdish Purushottamdas Mehta - Director
- Syed Asif Raza Rizvi - Director
- Vitalapuram Rajangam Krishna Subramanian - Director
- Venkatraman Subramaniam - Director
- Pascal Postel - Director
The latest financial statements of Wardex Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 27 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Wardex Pharmaceuticals is 33AAACW1036D1ZZ, registered in Tamil Nadu. The company has 18 GST registrations in all, of which 14 are active and 4 are cancelled or inactive. Other active GSTINs include 07AAACW1036D1ZU (Delhi), 08AAACW1036D1ZS (Rajasthan), 09AAACW1036D1ZQ (Uttar Pradesh).
The CIN (Corporate Identification Number) of Wardex Pharmaceuticals is U51397TN1946PTC005759. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Wardex Pharmaceuticals has 28 court cases on record: 26 filed by the company and 2 filed against it. 7 are pending. Most are in the high courts.
Wardex Pharmaceuticals was incorporated on 18 December 1946, making it 80+ years old. It is registered with the Registrar of Companies, Chennai.
Wardex Pharmaceuticals has 5 deals on record (5 secondary share transfers); the latest was in March 2024.
The peers of Wardex Pharmaceuticals by revenue are Elysium Pharmaceuticals Ltd, VHB Medi Sciences Limited, Jenburkt Pharmaceuticals Ltd, Nitin Lifesciences Limited, Wings Pharmaceuticals Pvt Ltd, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Errol James Desouza was appointed as Additional Director on 28 Jan 2025. Subhagmal Mohanchand Dadha ceased to be Director on 10 Feb 2023. Pascal Postel ceased to be Additional Director on 26 Nov 2021. Wardex Pharmaceuticals has 21 board changes on record in total.
Yes, Wardex Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0175893).
Wardex Pharmaceuticals has 3 MSME Form 1 returns on record between 2019 and 2020, listing 38 overdue payments to 25 micro and small suppliers. The latest return was filed on 18 Feb 2021.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages